PAION AG and US partner Forest Laboratories, Inc. today announced the top line results of the DIAS-2 (Desmoteplase In Acute Ischemic Stroke) study with the compound desmoteplase.
Top line results of phase III study in acute ischemic stroke (DIAS-2) do not demonstrate difference between desmoteplase and placebo
| Source: H. Lundbeck A/S
Attachments
